These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 15325872)

  • 1. Arsenic drinking water exposure and urinary excretion among adults in the Yaqui Valley, Sonora, Mexico.
    Meza MM; Kopplin MJ; Burgess JL; Gandolfi AJ
    Environ Res; 2004 Oct; 96(2):119-26. PubMed ID: 15325872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental Arsenic Exposure and Urinary 8-OHdG in Arizona and Sonora.
    Burgess JL; Meza MM; Josyula AB; Poplin GS; Kopplin MJ; McClellen HE; Stürup S; Lantz RC
    Clin Toxicol (Phila); 2007; 45(5):490-8. PubMed ID: 17503254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary arsenic methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-hyperendemic areas in southwestern Taiwan.
    Huang YL; Hsueh YM; Huang YK; Yip PK; Yang MH; Chen CJ
    Sci Total Environ; 2009 Apr; 407(8):2608-14. PubMed ID: 19187952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of urinary selenium and arsenic among pregnant women exposed to arsenic in drinking water.
    Christian WJ; Hopenhayn C; Centeno JA; Todorov T
    Environ Res; 2006 Jan; 100(1):115-22. PubMed ID: 16337848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DMPS-arsenic challenge test. I: Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate.
    Aposhian HV; Arroyo A; Cebrian ME; del Razo LM; Hurlbut KM; Dart RC; Gonzalez-Ramirez D; Kreppel H; Speisky H; Smith A; Gonsebatt ME; Ostrosky-Wegman P; Aposhian MM
    J Pharmacol Exp Ther; 1997 Jul; 282(1):192-200. PubMed ID: 9223554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to inorganic arsenic in drinking water and total urinary arsenic concentration in a Chilean population.
    Caceres DD; Pino P; Montesinos N; Atalah E; Amigo H; Loomis D
    Environ Res; 2005 Jun; 98(2):151-9. PubMed ID: 15820720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
    Kenyon EM; Hughes MF; Adair BM; Highfill JH; Crecelius EA; Clewell HJ; Yager JW
    Toxicol Appl Pharmacol; 2008 Nov; 232(3):448-55. PubMed ID: 18706920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z; Zhou J; Lu X; Gong Z; Le XC
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic speciation in human hair: a new perspective for epidemiological assessment in chronic arsenicism.
    Yáñez J; Fierro V; Mansilla H; Figueroa L; Cornejo L; Barnes RM
    J Environ Monit; 2005 Dec; 7(12):1335-41. PubMed ID: 16307093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis.
    Wu MM; Chiou HY; Hsueh YM; Hong CT; Su CL; Chang SF; Huang WL; Wang HT; Wang YH; Hsieh YC; Chen CJ
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):168-75. PubMed ID: 16806340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue distribution and urinary excretion of dimethylated arsenic and its metabolites in dimethylarsinic acid- or arsenate-treated rats.
    Adair BM; Moore T; Conklin SD; Creed JT; Wolf DC; Thomas DJ
    Toxicol Appl Pharmacol; 2007 Jul; 222(2):235-42. PubMed ID: 17559899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico.
    Coronado-González JA; Del Razo LM; García-Vargas G; Sanmiguel-Salazar F; Escobedo-de la Peña J
    Environ Res; 2007 Jul; 104(3):383-9. PubMed ID: 17475235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fasting on the pattern of urinary arsenic excretion.
    Brima EI; Jenkins RO; Lythgoe PR; Gault AG; Polya DA; Haris PI
    J Environ Monit; 2007 Jan; 9(1):98-103. PubMed ID: 17213949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intake of arsenic from water, food composites and excretion through urine, hair from a studied population in West Bengal, India.
    Uchino T; Roychowdhury T; Ando M; Tokunaga H
    Food Chem Toxicol; 2006 Apr; 44(4):455-61. PubMed ID: 16198037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan.
    Tseng CH; Huang YK; Huang YL; Chung CJ; Yang MH; Chen CJ; Hsueh YM
    Toxicol Appl Pharmacol; 2005 Aug; 206(3):299-308. PubMed ID: 16039941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of seafood consumption on the assessment of occupational exposure to arsenic by urinary arsenic speciation measurements.
    Arbouine MW; Wilson HK
    J Trace Elem Electrolytes Health Dis; 1992 Sep; 6(3):153-60. PubMed ID: 1483034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of arsenic species and insoluble arsenic in human urine.
    Chen YC; Amarasiriwardena CJ; Hsueh YM; Christiani DC
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1427-33. PubMed ID: 12433722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMPS-arsenic challenge test. II. Modulation of arsenic species, including monomethylarsonous acid (MMA(III)), excreted in human urine.
    Aposhian HV; Zheng B; Aposhian MM; Le XC; Cebrian ME; Cullen W; Zakharyan RA; Ma M; Dart RC; Cheng Z; Andrewes P; Yip L; O'Malley GF; Maiorino RM; Van Voorhies W; Healy SM; Titcomb A
    Toxicol Appl Pharmacol; 2000 May; 165(1):74-83. PubMed ID: 10814555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic exposure in Hungary, Romania and Slovakia.
    Lindberg AL; Goessler W; Gurzau E; Koppova K; Rudnai P; Kumar R; Fletcher T; Leonardi G; Slotova K; Gheorghiu E; Vahter M
    J Environ Monit; 2006 Jan; 8(1):203-8. PubMed ID: 16395480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans.
    Mann S; Droz PO; Vahter M
    Toxicol Appl Pharmacol; 1996 Oct; 140(2):471-86. PubMed ID: 8887465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.